What is NodThera?
NodThera is a pioneering biotechnology company dedicated to addressing chronic diseases by targeting inflammation at its source, specifically through the NLRP3 inflammasome pathway. The company's scientific approach aims to develop innovative medicines for a range of conditions including cardiovascular disease, obesity, and neuroinflammation. With a team of experienced biotech innovators, NodThera is positioned as a leader in the development of NLRP3-targeting therapies, seeking to impact millions of patients worldwide.
How much funding has NodThera raised?
NodThera has raised a total of $95M across 2 funding rounds:
Series A
$40M
Series B
$55M
Series A (2018): $40M with participation from Epidarex Capital, F-Prime Capital, Sofinnova Partners, and 5AM Ventures
Series B (2020): $55M led by 5AM Ventures, Cowen Healthcare Investments, Epidarex Capital, F-Prime Capital, Sofinnova Partners, Sanofi Ventures, and Novo Ventures
Key Investors in NodThera
5AM Ventures
5AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
Cowen Healthcare Investments
Cowen Healthcare Investments is part of Cowen, an independent financial services firm with a broad range of services including investment banking and research, focusing on the healthcare sector.
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm that builds breakthrough life science companies, acting as a trusted partner to founders and co-investors with deep scientific and industry networks.
What's next for NodThera?
The substantial enterprise-level capital infusion positions NodThera for accelerated growth and the advancement of its therapeutic pipeline. This strategic backing is expected to fuel further research and development, clinical trials, and potential commercialization efforts. The company's focus on a validated scientific mechanism for chronic inflammatory diseases suggests a trajectory towards becoming a key player in the biopharmaceutical sector, with potential for significant market penetration and patient benefit.
See full NodThera company page
